![]() ![]() Furthermore, individuals on maximally tolerated statin along with ezetimibe, a PCSK9 inhibitor should then be considered. Īccording to the 2018 Guideline on the Management of Blood Cholesterol,, clinicians should target at lowering LDL-C levels by more than 50% with maximally tolerated statin therapy in ASCVD. In very high-risk ASCVD individuals who are already under statin therapy and remain an increased LDL-C level (more than 70mg/dL) clinicians should then initiate additional non-statin therapy such as ezetimibe. ![]() ![]() Nevertheless, recent studies proposed the prognostic value of serum cholesterol efflux capacity in patients with coronary artery disease. Large clinical trials have shown that lowering LDL-C levels significantly reduce cardiovascular events and mortality rate whereas, according to current consensus, HDL-C is not a target for primary prevention in coronary artery diseases(CAD). Primary prevention recommendations for adults age between 40 to 75 years old With an LDL Level of 70 to 189 mg/dL. High levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C) are risk factors for coronary heart disease. The 2010 American College of Cardiology Foundation/American Heart Association guideline does not recommend measurement of apolipoproteins, size of lipid particles, and density for cardiovascular risk assessment. A fasting lipid panel is a strong recommendation for patients with type 2 diabetes, obesity, medications that may affect lipid levels, such as thiazides and beta blockers, and excessive intake of alcohol. Many current guidelines propose that nonfasting LDL-C holds similar significance to that of fasting LDL-C. Also, the accuracy of the fasting lipid profile depends on patients' compliance. Advantages of the non-fasting lipid profile are its accessibility clinically, simplicity for both patients and medical practitioners whereas the fasting lipid profile is inconvenient for patients and clinicians as it requires an additional visit. The rationale behind the discussion of fasting or non-fasting is because the triglycerides level can be affected by the last intake and the limitations of the Friedewald equation per se. Fasting or non-fastingWhile fasting LDL-C is still the standard for initiating lipid-lowering therapy, there has been a heated debate over fasting or non-fasting lipid profile among specialists. In an extensive cross-sectional analysis, Martin SS et al. proposed a novel calculation that is more accurate than the Friedewald equation regardless of fasting/nonfasting blood samples. There is an underestimation of intermediate-density lipoprotein(IDL), and some VLDL remnants which are considered atherogenic Here, we will discuss the indications for testing, the role of lipid profiles, and the relevant health care issues. Generally, a lipid profile or lipid panel consists of the following, Clinically, obtaining a lipid profile assists in the screening, diagnosing, and managing diseases. A high level of lipids, including cholesterol and triglycerides in the serum, which also termed as hyperlipidemia, leads to a higher risk of developing atherosclerotic cardiovascular disease (CVD). The level of cholesterol plays a vital role in cardiovascular diseases process. Each of these classes of lipoproteins transports cholesterol and triglyceride to its designated destinations. Lipids are circulating as lipoproteins, consisting of unesterified cholesterol, triglycerides, phospholipids, and protein. There are five major lipoproteins in blood: (1) chylomicrons (2) very low-density lipoprotein (VLDL) (3) intermediate-density lipoprotein (IDL) (4) low-density lipoprotein (LDL) and (5) high-density lipoprotein (HDL). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |